Valuation : MBody AI

Market Cap 1.98Cr 1.7Cr 1.6Cr 1.46Cr 2.75Cr 187.5Cr 2.76Cr 19Cr 7.38Cr 95Cr 7.42Cr 7.26Cr 316.26Cr P/E 2024
-0.23x
P/E 2025 2.44x
Enterprise Value 1.96Cr 1.69Cr 1.59Cr 1.45Cr 2.72Cr 185.58Cr 2.73Cr 19Cr 7.3Cr 94Cr 7.34Cr 7.18Cr 313.01Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day-2.44%
1 week-5.60%
Current month-5.60%
1 month-19.09%
3 months-45.25%
6 months-48.05%
Current year-43.56%
1 month 6.4
Extreme 6.4
10.48
Current year 6.4
Extreme 6.4
27.44
1 year 4.41
Extreme 4.410001
27.44
3 years 3.92
Extreme 3.920001
32.38
5 years 3.92
Extreme 3.920001
183.4
10 years 3.92
Extreme 3.920001
4,956

Financials

2024 2025
Net sales - -
Net income -2.51Cr -2.17Cr -2.04Cr -1.86Cr -3.5Cr -238.68Cr -3.51Cr -24Cr -9.39Cr -121.41Cr -9.44Cr -9.24Cr -402.58Cr 41.4L 35.71L 33.59L 30.6L 57.55L 39Cr 57.86L 3.97Cr 1.55Cr 20Cr 1.55Cr 1.52Cr 66Cr
Net Debt -1L -1L -1L -95.36T -2L -1.22Cr -2L -12.37L -5L -62.28L -5L -5L -2.06Cr -2L -2L -2L -2L -3L -1.93Cr -3L -19.47L -8L -98L -8L -7L -3.25Cr
Logo MBody AI
Check-Cap Ltd. is an Israel-based clinical-stage medical diagnostics company focused on colorectal cancer (CRC) screening solutions. The Company develops C-Scan, a preparation-free and non-invasive screening system designed to detect precancerous polyps and structural abnormalities in the colon. Its technology uses an ingestible capsule with ultra-low-dose X-ray imaging to scan the colon and collect diagnostic data. The C-Scan platform consists of an ingestible capsule, body-worn tracking and data collection components, and proprietary software that processes information and generates visual maps of the colon. The Company develops diagnostic technologies for gastrointestinal screening and early disease detection.
Employees
85
Sector
-
Date Price Change Volume
02/26/02 $6.400 -2.44% 4,589
26/26/26 $6.780 -16.09% 45,484
25/26/25 $8.080 +0.50% 19,625
  1. Stock Market
  2. Stocks
  3. MBAI Stock